BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11815730)

  • 21. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
    Calva D; O'Dorisio TM; Sue O'Dorisio M; Lal G; Sugg S; Weigel RJ; Howe JR
    Ann Surg Oncol; 2009 Aug; 16(8):2237-44. PubMed ID: 19472011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple endocrine neoplasia type 2.
    Marini F; Falchetti A; Del Monte F; Carbonell Sala S; Tognarini I; Luzi E; Brandi ML
    Orphanet J Rare Dis; 2006 Nov; 1():45. PubMed ID: 17105651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
    Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
    Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma.
    Barbot N; Calmettes C; Schuffenecker I; Saint-André JP; Franc B; Rohmer V; Jallet P; Bigorgne JC
    J Clin Endocrinol Metab; 1994 Jan; 78(1):114-20. PubMed ID: 7904611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour.
    Frank-Raue K; Döhring J; Scheumann G; Rondot S; Lorenz A; Schulze E; Dralle H; Raue F; Leidig-Bruckner G
    Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):550-3. PubMed ID: 20013610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia?
    Verga U; Ferrero S; Vicentini L; Brambilla T; Cirello V; Muzza M; Beck-Peccoz P; Fugazzola L
    Endocr Relat Cancer; 2007 Jun; 14(2):393-403. PubMed ID: 17639053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C-cell hyperplasia associated with chronic lymphocytic thyroiditis: a retrospective quantitative study of 112 cases.
    Guyetant S; Wion-Barbot N; Rousselet MC; Franc B; Bigorgne JC; Saint-Andre JP
    Hum Pathol; 1994 May; 25(5):514-21. PubMed ID: 8200646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome of "prophylactic therapy" for familial medullary thyroid cancer.
    Schellhaas E; König C; Frank-Raue K; Buhr HJ; Hotz HG
    Surgery; 2009 Nov; 146(5):906-12. PubMed ID: 19744457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Predictive genetic investigations. Individualization of diagnosis and treatment in families with multiple endocrine neoplasia type II].
    Engelbach M; Kunt T; Kann P; Manfras B; Hankeln T; Forst T; Pfützner A; Heerdt S; Walgenbach S; Lehnert H; Beyer J
    Dtsch Med Wochenschr; 2000 Jan; 125(3):37-44. PubMed ID: 10681997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of sex steroid hormone receptors in C cell hyperplasia and medullary thyroid carcinoma.
    Bléchet C; Lecomte P; De Calan L; Beutter P; Guyétant S
    Virchows Arch; 2007 Apr; 450(4):433-9. PubMed ID: 17333268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial nonmultiple endocrine neoplasia medullary thyroid carcinoma: an evolving clinical entity.
    McHenry CR; Oppenheim DS; Murphy T; Broughan T; Vogt D; Goldfarb WB
    Surgery; 1992 Oct; 112(4):728-32; discussion 732-3. PubMed ID: 1411944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Multiple endocrine neoplasia type 2].
    Niccoli-Sire P; Conte-Devolx B
    Ann Endocrinol (Paris); 2007 Oct; 68(5):317-24. PubMed ID: 17626779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma.
    Da Silva AM; Maciel RM; Da Silva MR; Toledo SR; De Carvalho MB; Cerutti JM
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5438-43. PubMed ID: 14602786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules.
    Costante G; Meringolo D; Durante C; Bianchi D; Nocera M; Tumino S; Crocetti U; Attard M; Maranghi M; Torlontano M; Filetti S
    J Clin Endocrinol Metab; 2007 Feb; 92(2):450-5. PubMed ID: 17119000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C-Cell Neoplasia in Asymptomatic Carriers of RET Mutation in Extracellular Cysteine-Rich and Intracellular Tyrosine Kinase Domain.
    Abi-Raad R; Virk RK; Dinauer CA; Prasad A; Morotti RA; Breuer CK; Sosa JA; Udelsman R; Rivkees SA; Prasad ML
    Hum Pathol; 2015 Aug; 46(8):1121-8. PubMed ID: 26033033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation.
    Shifrin AL; Ogilvie JB; Stang MT; Fay AM; Kuo YH; Matulewicz T; Xenachis CZ; Vernick JJ
    Surgery; 2010 Dec; 148(6):1274-80; discussion 1280-1. PubMed ID: 21134561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature.
    Rossi S; Fugazzola L; De Pasquale L; Braidotti P; Cirello V; Beck-Peccoz P; Bosari S; Bastagli A
    Endocr Relat Cancer; 2005 Jun; 12(2):281-9. PubMed ID: 15947103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
    Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of C-cell hyperplasia in patients with normal basal and pentagastrin-stimulated calcitonin.
    Scheuba C; Kaserer K; Kotzmann H; Bieglmayer C; Niederle B; Vierhapper H
    Thyroid; 2000 May; 10(5):413-6. PubMed ID: 10884188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.